• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds

Recent Advances in the Study of 2-Nitro-5-(1-piperazinyl)aniline (CAS: 96103-52-5) in Chemical Biology and Pharmaceutical Research

The compound 2-Nitro-5-(1-piperazinyl)aniline (CAS: 96103-52-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The compound's piperazine moiety and nitro group make it a versatile scaffold for further chemical modifications, which has led to its exploration in various drug discovery programs.

Recent studies have highlighted the role of 2-Nitro-5-(1-piperazinyl)aniline as a key intermediate in the synthesis of novel pharmacologically active molecules. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of kinase inhibitors targeting cancer-related pathways. The study utilized computational modeling and high-throughput screening to identify derivatives of 2-Nitro-5-(1-piperazinyl)aniline with enhanced binding affinity to specific kinase domains. These findings suggest that the compound could serve as a promising starting point for the design of next-generation anticancer agents.

In addition to its potential in oncology, 2-Nitro-5-(1-piperazinyl)aniline has also been investigated for its antimicrobial properties. A recent preprint on bioRxiv reported that derivatives of this compound exhibited potent activity against multidrug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The study employed a combination of in vitro assays and molecular docking simulations to elucidate the mechanism of action, revealing that the nitro group plays a critical role in disrupting bacterial cell wall synthesis. These results underscore the compound's potential as a scaffold for developing new antibiotics to address the growing threat of antimicrobial resistance.

Another area of interest is the compound's application in neurodegenerative disease research. A 2024 study in ACS Chemical Neuroscience explored the neuroprotective effects of 2-Nitro-5-(1-piperazinyl)aniline derivatives in models of Alzheimer's disease. The researchers found that certain derivatives could inhibit amyloid-beta aggregation and reduce oxidative stress in neuronal cells. These findings open new avenues for the development of small-molecule therapeutics targeting protein misfolding diseases, although further in vivo studies are needed to validate these effects.

The synthesis and optimization of 2-Nitro-5-(1-piperazinyl)aniline derivatives have also seen significant advancements. Recent publications in Organic Letters and Tetrahedron have described novel synthetic routes that improve yield and purity while reducing environmental impact. For example, a green chemistry approach using catalytic hydrogenation was reported to efficiently reduce the nitro group, enabling the production of diverse analogs with minimal waste. These methodological improvements are critical for scaling up production and facilitating structure-activity relationship studies.

Despite these promising developments, challenges remain in the clinical translation of 2-Nitro-5-(1-piperazinyl)aniline-based therapeutics. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive preclinical studies. However, the compound's modular structure offers ample opportunities for medicinal chemistry optimization, as evidenced by the growing number of patents filed in recent years covering its derivatives and applications.

In conclusion, 2-Nitro-5-(1-piperazinyl)aniline (CAS: 96103-52-5) represents a versatile and pharmacologically relevant scaffold with applications spanning multiple therapeutic areas. The latest research highlights its potential in oncology, antimicrobial therapy, and neurodegenerative disease treatment, supported by advances in synthetic chemistry and drug design methodologies. Future studies should focus on translating these findings into clinically viable candidates while addressing the remaining pharmacological challenges.

• 23491-48-7(5-(4-Methylpiperazin-1-yl)-2-nitroaniline)
• 7061-92-9(1,4-bis(2,4-dinitrophenyl)piperazine)
• 6270-12-8(1-(2-Nitrophenyl)piperazine Hydrochloride)
• 58910-37-5(Piperazine, 1-(2,4-dinitrophenyl)-4-methyl-)
• 59084-06-9(1-(2-Nitrophenyl)piperazine)
• 31284-04-5(1-(2,4-Dinitrophenyl)piperazine Hydrochloride)
• 62208-63-3(1-methyl-4-(2-nitrophenyl)piperazine)
• 1207461-22-0(2-nitro-3-(1-piperazinyl)-Benzenamine)
• 62208-64-4(Piperazine, 1-(2,4-dinitrophenyl)-4-phenyl-)
• 7251-04-9(1-methyl-4-(2-nitrophenyl)piperazine;chloride)